Stoke Therapeutics (NASDAQ:STOK) Upgraded at Chardan Capital

Stoke Therapeutics (NASDAQ:STOK) was upgraded by stock analysts at Chardan Capital to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

Several other research firms have also commented on STOK. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Wednesday. Wedbush increased their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Canaccord Genuity Group raised their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, JPMorgan Chase & Co. lifted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $31.00.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $27.93 on Wednesday. The business has a 50 day moving average price of $27.41 and a 200 day moving average price of $18.21. The company has a market capitalization of $1.60 billion, a P/E ratio of 41.69 and a beta of 1.32. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. On average, research analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Activity

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 40,472 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the sale, the director directly owned 364,246 shares of the company’s stock, valued at approximately $9,827,357.08. The trade was a 10.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward M. Md Kaye sold 25,000 shares of the stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $30.00, for a total value of $750,000.00. Following the transaction, the director directly owned 49,124 shares in the company, valued at approximately $1,473,720. This represents a 33.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 213,367 shares of company stock worth $5,110,464 in the last three months. 9.50% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. Dauntless Investment Group LLC acquired a new stake in shares of Stoke Therapeutics in the first quarter worth approximately $190,000. XTX Topco Ltd purchased a new position in Stoke Therapeutics during the first quarter worth approximately $267,000. US Bancorp DE boosted its holdings in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after purchasing an additional 11,108 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock valued at $18,515,000 after buying an additional 53,004 shares during the period. Finally, Invesco Ltd. increased its holdings in shares of Stoke Therapeutics by 117.0% during the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after buying an additional 14,118 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.